(PROJECT 1 - AN) Our overall goal in this proposal is to improve engraftment of anti-HIV gene modified hematopoietic stem/progenitor cells (HSPC) in vivo. HSPC based gene therapy holds great promise to provide long-term protection against HIV with the possibility of achieving a cure. However, studies to date have met with limited success largely due to the low efficiency of gene delivery into HSPC and subsequent hematopoietic reconstitution with anti-HIV gene modified cells. Overall we hypothesize that the efficiency of repopulation is important for the efficacy of HSPC-based gene therapy as apparent for the first case of HIV cure that was recently achieved by nearly complete bone marrow replacement by CCR5 deficient transplanted donor cells. However, unlike the first case of the HIV cured patient, complete bone marrow replacement by gene modified HSPC may not occur because of the limited efficiency of anti-HIV gene modified HSPC engraftment. Additionally, use of the intensive myeloablation procedure because of the presence of leukemia allowed in this first case of an HIV cure poses a high risk clinically. Therefore, in order to provide clinical benefit by HSPC gene therapy strategies, research is required to achieve more effective and safe procedures that can provide positive selection of genetically modified HSPC in patients. In this proposal, we will test a novel in vivo selection strategy that exclusively employs 6-thioguanine for both pre-conditioning and chemoselection of HPRT down-regulated genetically engineered HSPC, that is capable of enriching engraftment and long-term reconstitution of genetically engineered multi-pronged HIV resistant HSPC and progenies using a HIV infection established humanized mouse model. Our proposed research has a potential to break through the major obstacle in the field for HSPC gene therapy to enrich and efficiently repopulate gene-modified cells for the successful control of HIV disease without life long drug treatment and for HIV cure.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI117941-01
Application #
8899034
Study Section
Special Emphasis Panel (ZAI1-BP-A (J3))
Project Start
Project End
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$395,756
Indirect Cost
$112,756
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Khamaikawin, Wannisa; Shimizu, Saki; Kamata, Masakazu et al. (2018) Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1. Mol Ther Methods Clin Dev 9:23-32
Carrillo, Mayra A; Zhen, Anjie; Zack, Jerome A et al. (2017) New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. Transl Res 187:83-92
Zhen, Anjie; Peterson, Christopher W; Carrillo, Mayra A et al. (2017) Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLoS Pathog 13:e1006753
Suryawanshi, Gajendra W; Xu, Song; Xie, Yiming et al. (2017) Bidirectional Retroviral Integration Site PCR Methodology and Quantitative Data Analysis Workflow. J Vis Exp :
Zhen, Anjie; Carrillo, Mayra A; Kitchen, Scott G (2017) Chimeric antigen receptor engineered stem cells: a novel HIV therapy. Immunotherapy 9:401-410
Kitchen, Scott G; Zack, Jerome A (2016) Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. AIDS Patient Care STDS 30:556-561
Pernet, Olivier; Yadav, Swati Seth; An, Dong Sung (2016) Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev 103:187-201
Ali, Ayub; Kitchen, Scott G; Chen, Irvin S Y et al. (2016) HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. J Virol 90:6999-7006
Peterson, Christopher W; Haworth, Kevin G; Burke, Bryan P et al. (2016) Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. Mol Ther Methods Clin Dev 3:16007
Zhen, Anjie; Kamata, Masakazu; Rezek, Valerie et al. (2015) HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther 23:1358-1367